Patients with early-stage bladder cancer are often able to maintain their usual routines. Some may experience urinary ...

NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

Inlexzo is a new treatment for a type of bladder cancer in adults that hasn’t spread to the muscles and doesn’t respond to Bacillus Calmette-Guérin (BCG) therapy. It’s approved for treating non-muscle ...

Bladder control issues affect millions of people worldwide, impacting daily activities and quality of life. While common, these conditions remain treatable through various medical interventions, ...

For people with non–muscle invasive bladder cancer (NMIBC), the reality can be especially pronounced. The disease is often persistent, requiring repeated treatments, frequent monitoring, and ongoing ...

Bladder leakage, also known as urinary incontinence, is a common but often misunderstood condition that refers to the unintentional leakage of urine. About 25 million people in the United States have ...

A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously ...

Bladder cancer is a common cancer and one of the most costly to treat, yet there has been little change in the standard of care in 40 years. This panel will focus on the unmet needs in bladder cancer ...